Viatris (VTRS) EBIT (QoQ) (2020 - 2026)
Viatris (VTRS) EBIT (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.90% |
| Mar 31, 2026 | 58.64% |
| Dec 31, 2025 | -207.77% |
| Sep 30, 2025 | -23.26% |
| Jun 30, 2025 | 108.08% |
| Mar 31, 2025 | -1,503.00% |
| Dec 31, 2024 | -179.59% |
| Sep 30, 2024 | 194.16% |
| Jun 30, 2024 | -217.66% |
| Mar 31, 2024 | 144.86% |
| Dec 31, 2023 | -200.62% |
| Sep 30, 2023 | 22.35% |
| Jun 30, 2023 | -7.65% |
| Mar 31, 2023 | 298.61% |
| Dec 31, 2022 | -135.94% |
| Sep 30, 2022 | 2.08% |
| Jun 30, 2022 | -22.43% |
| Mar 31, 2022 | 1,011.60% |
| Dec 31, 2021 | -121.70% |
| Sep 30, 2021 | 848.12% |